Enzymatica publ AB (ST:ENZY) — Market Cap & Net Worth
Market Cap & Net Worth: Enzymatica publ AB (ENZY)
Enzymatica publ AB (ST:ENZY) has a market capitalization of $66.35 Million (Skr616.55 Million) as of May 4, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #20791 globally and #372 in its home market, demonstrating a -8.96% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Enzymatica publ AB's stock price Skr2.54 by its total outstanding shares 242735108 (242.74 Million). Analyse ENZY cash generation efficiency to see how efficiently the company converts income to cash.
Enzymatica publ AB Market Cap History: 2015 to 2026
Enzymatica publ AB's market capitalization history from 2015 to 2026. Data shows change from $99.35 Million to $66.35 Million (-8.09% CAGR).
Index Memberships
Enzymatica publ AB is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
First North Sweden PI
FNSESEKPI
|
$14.99 Billion | 0.44% | #49 of 281 |
Weight: Enzymatica publ AB's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Enzymatica publ AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Enzymatica publ AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.91x
Enzymatica publ AB's market cap is 0.91 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $99.35 Million | $27.91 Million | -$40.83 Million | 3.56x | N/A |
| 2016 | $68.12 Million | $36.48 Million | -$45.01 Million | 1.87x | N/A |
| 2017 | $128.36 Million | $59.45 Million | -$31.45 Million | 2.16x | N/A |
| 2018 | $57.45 Million | $52.56 Million | -$42.58 Million | 1.09x | N/A |
| 2019 | $103.67 Million | $61.31 Million | -$40.98 Million | 1.69x | N/A |
| 2020 | $488.31 Million | $111.25 Million | -$13.22 Million | 4.39x | N/A |
| 2021 | $228.22 Million | $57.24 Million | -$45.39 Million | 3.99x | N/A |
| 2022 | $117.55 Million | $48.95 Million | -$68.66 Million | 2.40x | N/A |
| 2023 | $103.05 Million | $50.90 Million | -$49.73 Million | 2.02x | N/A |
| 2024 | $41.27 Million | $45.58 Million | -$53.18 Million | 0.91x | N/A |
Competitor Companies of ENZY by Market Capitalization
Companies near Enzymatica publ AB in the global market cap rankings as of May 4, 2026.
Key companies related to Enzymatica publ AB by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #572 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.09 |
Enzymatica publ AB Historical Marketcap From 2015 to 2026
Between 2015 and today, Enzymatica publ AB's market cap moved from $99.35 Million to $ 66.35 Million, with a yearly change of -8.09%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr66.35 Million | +33.68% |
| 2025 | Skr49.63 Million | +20.25% |
| 2024 | Skr41.27 Million | -59.95% |
| 2023 | Skr103.05 Million | -12.33% |
| 2022 | Skr117.55 Million | -48.49% |
| 2021 | Skr228.22 Million | -53.26% |
| 2020 | Skr488.31 Million | +371.03% |
| 2019 | Skr103.67 Million | +80.46% |
| 2018 | Skr57.45 Million | -55.24% |
| 2017 | Skr128.36 Million | +88.43% |
| 2016 | Skr68.12 Million | -31.44% |
| 2015 | Skr99.35 Million | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Enzymatica publ AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $66.35 Million USD |
| MoneyControl | $66.35 Million USD |
| MarketWatch | $66.35 Million USD |
| marketcap.company | $66.35 Million USD |
| Reuters | $66.35 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Enzymatica publ AB
Enzymatica AB (publ), a life science company, develops and sells medical devices for infection-related diseases. The company's product includes ColdZyme, a mouth spray that protects against the upper respiratory viruses that can cause cold and flu symptoms. It also provides enzyme formulations for skin care. The company was incorporated in 2007 and is headquartered in Lund, Sweden.